Please login to the form below

Not currently logged in
Email:
Password:

II-ON

This page shows the latest II-ON news and features for those working in and with pharma, biotech and healthcare.

Sangamo’s first gene-editing trial doesn’t convince investors

Sangamo’s first gene-editing trial doesn’t convince investors

II and cause the widespread tissue and organ damage that eventually shortens patients’ lives. ... Withdrawal from weekly ERT infusions would be “a very meaningful outcome” for patients with MPS II, he added.

Latest news

More from news
Approximately 1 fully matching, plus 129 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... Amendment to 2015 agreement. 80. Inovio

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    1 agonist that recently completed a phase II study. ... Israeli company Oramed whose ORMD-0801 candidate is in phase II.

  • Pharma deals in May 2015 Pharma deals in May 2015

    Making an upfront payment of $5m, the deal carriesmilestones of $105m for the phase II-ready asset. ... The option is exercisable on completion of the phase II studies in acute kidney injury related to sepsis.

  • Pharma deals in April 2015 Pharma deals in April 2015

    In a phase II study on DLBC SAR3419 achieved a 43.9% objective response rate, to which investigators heralded its potential as a second-line therapy. ... milestones and 4SC will be entitled to double-digit royalties on products sales on resminostat. .  

  • Choices, choices: the rapidly evolving HIV treatment landscape Choices, choices: the rapidly evolving HIV treatment landscape

    However, the II component of Triumeq (dolutegravir, brand name Tivicay) has experienced rapid uptake in Germany and is competing with established antiretrovirals. ... The question is, which II-containing STR will physicians prescribe? The first

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Flex Pharma appoints new R&D president Flex Pharma appoints new R&D president

    In partnership with CMO Tom Wessel, my former Sepracor colleague, we are poised to execute on our US phase II development plans.”. ... With their successful partnership from their time at Sepracor, Bill and our CMO, Dr Tom Wessel, are a great team to

  • Parexel strengthens clinical leadership Parexel strengthens clinical leadership

    Dr Andersson's specific responsibilities include managing client relationships for phase II and phase III programmes on a global basis. ... This follows on from his role at Accenture where he oversaw technology, consulting and business services for

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Forecasting in Forgotten Markets

    Managed by SV Life Sciences the fund is focused primarily on Phase I and II research and aims to help share the risks associated with early drug discovery whilst reducing duplication ... with an internet connection whilst saving on search costs

  • A forward march for adaptive designs

    While the observed relationship between dose and efficacy for many drugs is often non-linear, the majority of phase II trials reported on ClinicalTrials.gov in the ten years between 2002 ... Getting the dose right at phase II has become a rallying cry

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics